Open label, non controlled, non randomized, interventional pilot study to evaluate the response rate after induction therapy with Docetaxel (T)and Cisplatin (P) in unresectable locally advanced squamous cell carcinoma of head and neck
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Metoclopramide; Ondansetron
- Indications Head and neck cancer
- Focus Therapeutic Use
- 29 Dec 2011 Status changed from recruiting to completed.
- 03 Oct 2011 New trial record